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Background: The International Committee of Medical Journal Editors (ICMJE) Recommendations set ethical and
editorial standards for article publication in most leading medical journals. Here, I examine the strengths and
weaknesses of the Recommendations in the prevention of commercial bias in industry-financed journal literature, on
three levels – scholarly discourse, article content, and article attribution.
Discussion: With respect to overall discourse, the most important measures in the ICMJE Recommendations are for
enforcing clinical trial registration and controlling duplicate publication. With respect to article content, the ICMJE
promotes stringent author accountability and adherence to established reporting standards. However, the ICMJE
accepts the use of commercial editorial teams to produce manuscripts, which is a potential source of bias, and
accepts private company ownership and analysis of clinical trial data. New ICMJE guidance on data sharing will
address but not eliminate problems of commercial data access. With respect to attribution, the Recommendations
oppose guest authorship and encourage clear documentation of author contributions. However, they exclude
writers from coauthorship; provide no specific advice on the attribution of commercial literature, for instance with
respect to company authorship, author sequence or prominent commercial labeling; and endorse the use of fine
print and euphemism. The ICMJE requires detailed author interest disclosures, but overlooks the interests of non-
authors and companies, and does not recommend that interests most salient to the publication are highlighted.
Together, these weaknesses facilitate “advocacy”-based marketing, in which literature planned, financed and
produced by companies is fronted by academics, enabling commercial messages to be presented to customers by
their respected clinical peers rather than companies themselves.
Conclusions: The ICMJE Recommendations set important research and reporting standards, without which
commercial bias would likely be a significantly greater problem than it is today. However, they also support
practices of commercial data control, content development and attribution that run counter to science’s values of
openness, objectivity and truthfulness. These weaknesses could be addressed with appropriate modifications to the
Recommendations. The ICMJE should also disclose its own commercial interests and funding – not least because
publishing organizations that finance it and pay the salaries of some member editors derive substantial revenues
from industry.
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Commercialization of academic medical literature is an
important concern for journals, their readers and pre-
scribing doctors. Good industry science should be
welcomed into scholarly literature, but commercial
bias may occur on several levels (Table 1). At the
level of academic discourse, commercial decisions
about which projects to undertake, data to publish,
arguments to propose and articles to develop may
distort the volume, distribution and balance of topics,
opinions and authorship within medicine’s literature
[1–3]. At the level of article content, commercial con-
siderations may affect the composition of articles, the
design, data coding, analysis and interpretation of the
studies that inform them, the findings they highlight,
the opinions they express and the language they use
[1–13]. Such influence may be exerted through
numerous channels, including company design of tri-
als, analysis, interpretation and ownership of trials
data, the use of hired contractors, the use of com-
pany coauthors, the use of commercial editorial teams
to develop manuscripts and the selection of accom-
modating academics to work on industry projects.
Finally, with respect to the attribution of commercial
articles, the identities, roles and interests of contri-
butors and stakeholders may be communicated to
readers in a misleading way. In particular, the role of
companies may be downplayed and that of academic
recruits exaggerated, for instance by placing aca-
demics at the head of the author byline and creditingTable 1 Potential commercial bias in medical journal articles, and IC
Level of bias (References) Examples
Academicdiscourse and
commercial planning [1–3]
• Clinical trials: what studies to undertake,
recruit as partners, whether and how to pu
• Publications: number, theme, placement,
and authorship of articles.
Article content [1–13] • Clinical trials: design, conduct, discontinu
and interpretation.
• Data misrepresentation, fabrication and f
• Review criteria and literature search.
• Insertion of commercial “key messages.”
• Language and rhetoric.
Article attribution
[1, 2, 13–15]
• Spinning the sum effect of authorship, co
acknowledgements, text, labeling, etc.
• Depends on what readers perceive, not m
disclosed.
• Advocacy-based marketing foregrounds
academic authors while obscuring the pro
of commerce using small print, vague lang
omission.companies only in minor author placements and fine
print [1, 2, 13–15]. Such abuses of attribution are the
basis of “advocacy”-based marketing, in which, for
reasons of endorsement, commercially-instigated data
and argument are presented to customers by their
own respected peers rather than companies them-
selves [2, 15–18].
The International Committee of Medical Journal Edi-
tors (ICMJE) is preeminent in setting editorial standards
for medical journals. Its Recommendations – previously
known as the Uniform Requirements for Manuscripts
(URM) [19] – have gradually evolved since their debut
in 1978, and currently set standards on authorship, con-
flict of interest, submission and review, publishing and
editorial issues, and manuscript preparation. They have
been adopted by nearly 2000 journals including most
leading titles, although ICMJE membership is limited to
a handful of top journals, some more minor and non-
English language journals, the US National Library of
Medicine and the World Association of Medical Editors.
Several past and present ICMJE editors have taken prin-
cipled public stands against commercialization within
medicine, [5, 20, 21] and the current Recommendations
include measures that help check commercial bias on all
three levels I have described. Yet the Recommendations
are also embraced by industry, including trade associa-
tions of the publishing, writing, marketing and pharma-
ceutical sectors [22–25] and this raises the question of
whether the ICMJE’s existing measures to address the
problem of industry bias are adequate, or whetherMJE protection





• Limited options available to ICMJE.
• Clinical trial registration (III L).
• Duplicate/prior publications (III D).
ation, analysis
alsification.
• Limited options– heavily reliant on peer review.
• Contributor listings (IIA 1).
• Stringent author accountability (IIA2).
• Access to data (IIB, IIB 2).
• Authors’ right to publish.
• Reporting guidelines (IV A2).
• Commercial supplements and series – journal’s
editorial control maintained (IIIG).







• Extensive options – but poorly developed.
• Ban on ghost authorship (II A2).
• Funding source, trial identifier listed visibly in
Abstract (IV A3).
• Contributorship, interest declarations and “Sources
of support” sections provide limited benefits but
involve small print (IIA, IIB, IV A3).
• Declaration of product being marketed – but only
for supplements (IIIG).
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how the then-ICMJE authorship guidance was in fact
commodious to marketing, [14, 26] prompting revision
by the ICMJE. Here, I have examined the entire Rec-
ommendations rather than the authorship formula
alone, evaluating every section in respect of my direct
working knowledge of industry practices. I identify
numerous protections against commercial distortion,
but also widespread weaknesses that facilitate market-
ing practices. I argue that these weaknesses derive not
only from ignorance about marketing, but from long-
standing conceptual shortcomings within editorial
thought and publication ethics.Discussion
ICMJE measures to address bias at the level of discourse,
content and attribution are summarized in Table 1. TheTable 2 Section by section: strengths and weaknesses of the ICMJE
2015 Recommendations)
Section Strengths
IIA1 Contributor listings • Bookkeeping of author accountability.
• Helps enforce integrity of publication.
II
A2
Authorship formula • Encourages high scientific standards.
• Encourages rigorous checking by authors.
• Bans guest authorship.
II
A3







II B Conflict of interest • Comprehensive net for author financial
interests.
II B Role of funding
source
• Company role in conducting research,
decision to publish reported.
II B Access to data • Discourages restrictions on author access to
data.
IIB Right to publish • Authors discouraged from agreeing
limitations to their right to publish.
IIID Overlapping
publications




• Editorial control defended.
• Notification of product being marketed.
III L Trial registration • Helps locate published commercial trials.





• CONSORT compliance required.














• Reveals involvement of company to readers.
• Also identifies contract research organizations.strengths and weaknesses of successive sections of the
Recommendations are summarized in Table 2.
Discourse-level bias
The ICMJE’s options to prevent discourse-level bias are
limited, since the Recommendations are largely con-
cerned with individual submissions to journals rather
than the research and planning that precedes them.
Nonetheless, several measures have been introduced, in-
cluding limited measures on prior and repeat publica-
tion, practices which might be used by marketing to
increase visibility of a commercial product, and most
importantly, trial registration. Since 2005, the ICMJE has
insisted that trials are registered at or before patient en-
rollment begins, at a major public registry; this measure
was specifically designed to address the problem of se-
lective reporting of trials [27]. The United States Food
and Drug Administration Amendment Act of 2007 hasRecommendations as a barrier to marketing bias (December
Weaknesses
• Do not separate academic and company coauthors.
• Small print, vague language assist attribution bias.
• Facilitates byline avoidance.
• No advice on author order.
• No company-level authorship or accountability.
• Omit key commercial information.
• Small print, vague language assist attribution bias.
• Supports commercial production of ghostwritten manuscripts.
• Facilitates and downplays commercial content influence.
• Salient interests not highlighted.
• No contributor interests.
• No corporate interests.
• No requirement to report company instigation, database ownership or
identity of marketed product.
• No requirement for independent statistical analysis.
• No demand for contractual rights to data access and unrestricted usage.
• Should insist on contractual rights guaranteeing publishing rights for
academic coauthors.
• Limited ability to prevent repetition of commercial content.
• None – but should apply to all commercially financed articles.
• None.
• Readers referred to EQUATOR and National Library of Medicine (NLM)
listings of guidelines - these include trade guidelines compatible with
marketing.
• The terms “funding,” “support” and “sponsorship” misrepresent actual
instigating/proprietary role of commerce.
• Stipulation is vaguely worded and omits key details e.g. company
instigation, database ownership, identity of marketed product.
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ing the results to be deposited in a publicly available
database [28]. It is important to recognize the role
played by the ICMJE in driving these improvements in
public knowledge about industry research.
Content-level bias
It is largely for peer reviewers to identify content bias,
although the ability of peer review to cope with the vol-
ume and technicality of industry material has been ques-
tioned [5]. The ICMJE does, however, place rigorous
accountability upon authors, as discussed below in re-
spect of authorship, and demands adherence to the Con-
solidated Standards of Reporting Trials (CONSORT)
[29]. Together, trial registration and CONSORT adher-
ence should ensure that all prospectively defined end-
points are reported in ICMJE-compliant journal articles
– although these measures cannot control how results
are framed, interpreted and spun.
Data ownership, analysis and access
A longstanding area of weakness for the ICMJE concerns
company clinical trials data. The ICMJE does not require
independent data analysis, or the academic authors to
have possession of, or to have looked at, the full data
themselves. All that is required is that they should be
granted “access” to the data if they request it. In practice,
many academic authors only see a results summary pre-
pared by the company. Section IIB of the Recommenda-
tions advises authors to “avoid entering in to
agreements” with companies that might limit their ac-
cess to the basic data, but this merely advises against re-
strictive agreements, whereas it should insist on
contracts requiring senior academic authors to have full,
immediate and enduring use within their institutions of
the anonymized patient-level database, with unrestricted
rights of analysis, comparison and dissemination.
Concerns about the meaning of “access to data” and
similar proposals to these have been discussed by a
number of scholars [30–33]. Accordingly, the most im-
portant current development in the ICMJE Recommen-
dations is the impending introduction of guidance on
data sharing [34]. Pharmaceutical companies have long
resisted making trials data publicly available, chiefly on
the grounds that other companies might mine it for
their own drug development programs, although these
arguments have been criticized [32, 33]. A greater prob-
lem would likely be data exploitation by competitors for
their own products’ commercial benefit. This could lead
to escalating scientific misinformation, negative spin and
fatuous research as companies with competing products
mined one another’s data to joust for advantage.
There is therefore a plausible case for preventing com-
panies from accessing other companies’ patient-leveldata, although protocols, summary results and clinical
study reports should be publicly available for all trials.
Independent academic groups should, however, have full,
retrospective access to clinical record forms and patient-
level data, including unpublished trials, for any drug
with at least one approved indication in any market [32,
33]. Furthermore, any form of data analysis whatsoever
should be permitted, including head-to-head compari-
sons with competitors and pooled analyses across trials
from different manufacturers. New organizations inde-
pendent of companies and researchers would be neces-
sary to manage these arrangements.
It is unlikely the initial ICMJE guidance on data shar-
ing will approach these standards. The draft ICMJE pro-
posals released in January 2016 suggested requiring data
sharing only in relation to results reported in the pub-
lished article, rather than full study databases, and made
no mention of protocols, clinical study reports or clinical
record forms [34]. Furthermore, the proposals indicated
potential ICMJE willingness to accept, and help enforce,
data sharing agreements restricting what analyses would
be permissible. Therefore, while the introduction of an
ICMJE data sharing policy is welcome, it may prove un-
duly accommodating of commercial restrictions – an
outcome which could establish a barrier, not a gate, to
proper data sharing. One positive feature of the draft
proposals was a requirement for the data sharing plan to
be included as a component of public trial registration.Manuscript development
An important area of weakness for the ICMJE concerns
manuscript development, which may be a source of con-
tent bias. Firstly, academics performing key roles in in-
dustry projects including drafting are more likely to have
financial ties to industry than their academic coauthors
[35]. A second means of potential influence is the use of
employees as coauthors – they may be heavily involved
in manuscript development, and serve as a conduit for
input from unnamed colleagues, yet receive only incon-
spicuous credit in the middle of the byline.
The ICMJE offers no guidance on employee coauthors,
but does address a third potential conduit for commer-
cial influence on manuscript development, the use of
trade writers. Many academics in other fields would con-
sider the use of trade writers to draft learned text an af-
front to scholarship, but medical journals and the
ICMJE have embraced the practice, on the basis that
writing is supposedly a technical, not an intellectual task.
Perhaps the most signal exchange occurred in 1995 in
JAMA, which though 20 years old merits quotation [36].
DeBakey and DeBakey defended the traditional scholarly
perspective that writing is an intellectual task, such that
trade writers should have no place in learned literature:
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ghostwriting; the first involves inconsiderable changes,
the second composing… Writing a competent medical
report requires thinking logically, analyzing data
rigorously and interpreting them critically, organizing
relevant material coherently, and presenting results in
a lucid form. Writing, if done thoughtfully, may
disclose an ill-defined thesis, experimental flaw, or
faulty data analysis. How many ghostwriters apply
such scrutiny? How can the reader judge the scientific
merit of a ghostwritten article? It may be eloquent
and persuasive without being true or valid….. Instead
of bringing ghostwriters out of the closet, let's flush
them out of the profession.… Let's exorcize the
ghosts, not acknowledge them.
But JAMA editors Flanagin and Rennie took the con-
trasting view that trade writing is mere “literary assist-
ance” for inarticulate doctors, and therefore acceptable:
… a writer, who solely contributes to the writing of a
manuscript – visibly or not – does not automatically
qualify for authorship…. such assistance should be
disclosed, not prohibited. By acknowledging
substantial writing and editing assistance, we are not
judging whether such aid biases a report… We know
of many scientists who require such assistance. … So
why shouldn't the actual drafter of the manuscript be
publicly credited for such a contribution in the
acknowledgment, especially if the writer is employed
or paid by a company with a commercial interest in
the report? … crediting literary assistance is
thoroughly compatible with our efforts to preserve
the integrity of scientific publication.
Today’s ICMJE policy follows the JAMA view; yet the
DeBakeys’ view of writing as composition was correct,
and its rejection has facilitated commercialization of aca-
demic medical literature. What is most lacking in the
JAMA-ICMJE viewpoint is an understanding that while
company editorial teams may not have a true expert’s
knowledge of the medical subject matter of the articles
they draft (though most trade writers have science
PhDs), theirs is an intellectual contribution to content
nonetheless, and their expertise often exceeds that of the
academic authors in two respects - the intellectual task
of manuscript composition, and more importantly, their
awareness of the commercial nuances of the text. Fur-
thermore, their work is reviewed by company personnel
who include true subject-matter experts. In privileging
the expertise of academic authors and treating other
contributions as auxiliary, medicine’s editorial commu-
nity has played into the hands of marketing, blinkering
itself to the ease with which highly intelligent parties,who for marketing reasons wish to be perceived as mere
“assistants”, can subtly frame and spin the content of lit-
erature in the service of commerce.
Attribution and disclosure
Arguably the greatest inadequacies of the current Rec-
ommendations concern the attribution of journal arti-
cles. The word “attribution” is not currently used in the
Recommendations, and it is important for the editorial
and ethics communities to consider carefully what attri-
bution involves and how it can be subjected to system-
atic commercial spin.
Attribution is not coextensive with authorship. Cor-
rectly understood, the attribution of a journal article en-
compasses everything it communicates in order to
inform readers about its provenance and development,
the identity of its stakeholders and contributors, and
their roles and interests. Attribution involves authorship;
author sequence; contributor listings; statements in the
abstract; and sometimes information provided in the
title, footnotes or labeling. Interest declarations also have
a bearing upon attribution since they point to the moti-
vations at play in the work. It is also very important to
note that attribution is not merely a matter of documen-
tation, but of communication with the reader. Accord-
ingly, the parties that played the most important role in
developing the article and conducting the research it de-
scribes should be represented most prominently.
Unfortunately, the attribution of industry literature is
frequently subjected to commercial bias in the service of
“advocacy”-based marketing. As discussed above, aca-
demic authors are commonly highlighted, while the role
of the company is downplayed through minor author
placements, vague disclosures and small print [14, 15].
The ICMJE Recommendations support or tolerate these
unethical practices.
Authorship
Authorship is the most important component of attribu-
tion within scholarly literature, and has a privileged
standing within medicine. The ICMJE authorship for-
mula is highly restrictive, and currently has four
conditions:
1. Substantial contributions to the conception or
design of the work; or the acquisition, analysis, or
interpretation of data for the work; AND
2. Drafting the work or revising it critically for
important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the
work in ensuring that questions related to the
accuracy or integrity of any part of the work are
appropriately investigated and resolved.
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were truly involved in the work, and are willing and able
to account for it. Its stringency reflects the need for a
consistent mechanism to regulate authorship on projects
with numerous participants, but it also reflects the shock
suffered by academic medical publishing in the 1980s
and 1990s, when fraudulent literature was exposed and
personal research integrity became an overriding ethical
concern [37, 38]. Accordingly, the ICMJE insists that au-
thors must have done the research (Condition 1),
worked on the manuscript (Condition 2) and approved
the published text (Condition 3). The fourth condition
seeks to reconcile author accountability with varying au-
thor expertise. Most clinicians cannot, for instance, be
technically responsible for an article’s statistics, or statis-
ticians for clinical interpretation, but both must ensure
issues arising in either domain are properly addressed.
With respect to commerce, the effects of the ICMJE
authorship formula are mixed. Creditably, it militates
against lax scientific standards, compels authors to re-
view research and text rigorously, and opposes “guest
authorship” – that is, inclusion of authors whose contri-
butions are too modest to merit author status. These
benefits apply in commercial and noncommercial work
alike. There are, however, four aspects of the ICMJE ap-
proach that prove commodious to marketing. Firstly,
there is no facility for corporate authorship. This reflects
the longstanding preoccupation of medicine’s editors
with personal accountability, illustrated by Rennie’s sen-
timent that “attached to every article there be actual be-
ings, prominently identified, who are prepared to be
accountable for all aspects of the reports” [39]. Yet in
commercial publications, the company itself usually
plays a highly active role in the conception, design, con-
duct and analysis of research, and in planning and draft-
ing manuscripts. Typically this involves numerous
individuals, both within the company itself and in its
hired agencies [2, 3, 14]. Many of these individuals do
not qualify as authors in their own right by the ICMJE
formula, or indeed as non-author contributors. Corpor-
ate authorship is a reality of industry science, but in fo-
cusing with such stringency on individuals rather than
requiring companies themselves to be credited with an
authorial or similarly prominent attribution, the current
ICMJE guidance facilitates de facto corporate ghost
authorship.
Secondly, there is no adequate ICMJE guidance on au-
thor sequence. In particular, there is no injunction
against the “academic frontloading” of author bylines for
the purposes of credibility [14, 15]. So ingrained and ex-
pected has academic frontloading become that many
companies now view it as a necessity for maximizing the
likelihood their work will be accepted by journals for
publication [40, 41].Thirdly, the ICMJE takes the remarkable stance that
no medical journal article need ever be written by any of
its named authors. Clause 2 of the authorship formula
states that revision alone is required; and further text
below the formula bars what is ambiguously termed
“writing assistance” from byline credit. Consequently, a
significant intellectual and commercial contribution to
the published work is credited only in fine print. The
Recommendations thereby sanction the industrial pro-
duction of content using ghostwriting – “where a profes-
sional medical writer prepares a manuscript on behalf of
a named author, but the writer is not listed as an author”
[42]. The ICMJE should replace this discreditable policy
with the approach exemplified by Neurology, and require
writers to be credited as authors [43].
Fourthly, the Recommendations do not specifically re-
quire key contributors to be authors. The ICMJE for-
mula was conceived as a means of limiting authorship,
and does not address the possibility that parties who
should be authors might prefer not to be – notably,
commercial parties seeking to direct reader attention to
academic authors for purposes of endorsement. Text in-
troduced in 2013 states that individuals substantially in-
volved in the work and therefore meeting Condition 1
“should have the opportunity” to work on the manu-
script and meet Conditions 2–4, therefore becoming au-
thors. Yet there is no specific demand they should do so,
and companies have been known to reduce the number
of their deserving employees who become coauthors in
order to reduce company visibility [40]. A more robust
approach would be to require all those substantially in-
volved in research to be compulsorily identified as con-
tributors, and a written explanation provided to editors
when individuals so named chose not to participate as
authors.
Contributorship
The ICMJE does not formally recommend contributor
listings, but “strongly encourages” them. Contributor
listings benefit noncommercial and commercial publica-
tions alike, permitting a more granular account of credit
and responsibility, and providing a record should con-
cerns about misconduct arise [37]. In industry literature,
contributor listings have the additional advantage of
helping identify the roles played by industry coauthors.
Currently, contributor listings vary considerably
among journals. The clearest and most informative for-
mat is exemplified by JAMA, which uses structured end-
notes organized by contribution type to record the roles
of both authors and non-authors. Currently, the CRediT
(Contributor Roles Taxonomy) program, a Consortia
Advancing Standards in Research Administration Infor-
mation (CASRAI) initiative, [44, 45] is attempting to
develop a standardized approach similar to JAMA’s but
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proach is likely to gain support from journals and in due
course the ICMJE. The fourteen categories are broadly
reasonable, although certain key industry roles such as
instigation, finance, data ownership and product market-
ing are absent. The success of the system in respect of
industry will depend on whether these omissions are ad-
dressed and whether companies, as well as individuals,
are to be systematically credited.
But while contributor listings are important, they also
illustrate the failure of medicine to distinguish ad-
equately between documentation and communication.
The former requires only fine-print; the latter is
thwarted by it. Rennie and colleagues’ 1997 proposals
suggested contributorship should replace authorship; but
they also argued for retention of the byline, for “those
who contributed most substantially to the work” [46].
This amounts to a de facto retention of authorship, in
contrast Smith’s call for authorship’s genuine replace-
ment by a “film credits” approach [47, 48]. Furthermore,
Rennie and colleagues called for the contributions them-
selves, including the names of non-byline contributors,
to be documented in fine print. Alternative proposals by
Fotion and Resnick sought to establish more conspicu-
ous credit for contributors who were not byline authors,
avoiding what Fotion derided as “the almost meaning-
less” option of crediting them in a footnote [49, 50]. The
ICMJE has broadly followed Rennie’s proposals, save that
those privileged with byline status continue to be termed
and indexed as authors. While the documentary function
of contributor listings is an important advance, it there-
fore provides marketing with a fine print format wherein
the role of the company can be mapped to inconspicu-
ous employees, while recruited academic authors con-
tinue to dominate reader perceptions.
A critical weakness: reader notification and labeling
The weaknesses of the Recommendations with respect to
authorship and contributorship would in large measure
be negated if there was also guidance on prominent la-
beling of industry publications, requiring readers to be
notified at the outset of an industry article’s true proven-
ance, ownership and commercial functions. This could
be achieved through a variety of means, for instance
naming the company responsible for the work as a lead
author, or in the title, or in a label at the head of the
text. Such notification would need to be conspicuous,
clearly worded, and apparent when the article abstract
was viewed online. Clear commercial labelling would
also combat the use of academics for endorsement and
the production of scholarly articles as marketing
vehicles.
Unfortunately, the Recommendations contain no provi-
sions for prominent commercial labeling, except incertain non-standard publication settings (Table 2). Most
usefully, section IVA states that “Funding sources should
be listed separately after the Abstract”, and some jour-
nals now credit companies with “funding” or “support”
at this location. Yet while this is commendable, the lan-
guage is misleading and euphemistic, because pharma-
ceutical companies are not mere sources of “funding”.
Indeed, it is notable throughout the Recommendations,
that oblique language is used when referring to industry.
The words “company”, “business”, “corporation”,
“pharmaceutical” and “marketing” are entirely absent,
and the terms “sponsor” and provider of “support” are
preferred. This helps sustain a false depiction of industry
research, in which the article and the study it reports ap-
pear to belong fundamentally to the authors, while the
company that is in fact responsible for both and which
owns the data appears to have a secondary and subservi-
ent status.
Conflict of interest reporting
The ICMJE publishes a detailed conflict-of-interest form
which has helped standardize author interest disclosures.
The importance of author interest disclosures has re-
cently been debated within the editorial community and
the standards set by the Recommendations have been
defended [51, 52]. Notwithstanding their importance,
however, the ICMJE disclosure guidance has limitations
in respect of commercial projects. Firstly, only authors
are required to disclose interests. Other contributors are
not, and if the byline is evaded, no disclosure is required.
Secondly, the confusion between documentation and
communication is once again evident, in that: there is
no provision for bringing the most salient interests –
namely, authors’ relationships with the company market-
ing the drug – to the attention of readers. Consequently,
these relationships are often rendered inconspicuous by
being reported amid a mass of other disclosures, and in
small print. Finally, there is no requirement for disclos-
ure of other stakeholder interests – most importantly,
company interests such as the identity of the drug being
marketed in the article. Journals too are stakeholders
whose interests should be reported [53–55].
Interest disclosures present a challenge for print jour-
nals because of space considerations; some journals refer
readers to online author disclosures. Such problems will
increase if articles are required to list more extensive in-
terests including those of stakeholders and non-author
contributors. Three steps appear necessary to address
these difficulties: firstly, to ensure that critical interests,
such as company finance and authors’ relationships with
the company, are brought conspicuously to readers’ at-
tention at the outset; secondly, to accompany articles
online with standardized grids documenting the interests
of companies, authors, contributors and the journal; and
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author interests, as advocated by Rasmussen and col-
leagues [56]. Such registries might be the responsibility
of the state, academic institutions or potentially author
identification systems such as ORCID [57]. All these
possibilities require discussion and debate, but as with
trial registration and data sharing, interest registration
provides an opportunity for the ICMJE to constructively
influence research culture.
Factors underlying ICMJE commercial policy weakness
It is clear that without the Recommendations, the quality
of medical literature, including commercial medical lit-
erature, would be significantly poorer than it is today.
Equally, however, the marketing of blockbuster drugs in-
volves industry-financed literature that is commercially
biased but ICMJE-compliant. The ICMJE accepts ar-
rangements in which companies instigate trials, analyze
and own the data, and plan and produce manuscripts,
but attribute these projects primarily to recruited aca-
demics. These academics are not guest authors insofar
as they contribute actively to projects, and yet they are
contingent: were they not available, other academics
could and would be recruited, and publications with
similar content and identical commercial functions
would be generated. The ICMJE Recommendations fa-
cilitate these practices, and showcase in their own text a
euphemistic language of “sponsors”, “funding” and “sup-
port” which falsely implies the corporate masters of this
research are mere facilitators.
These weaknesses in the ICMJE Recommendations are
of long standing, and likely reflect a diversity of under-
lying causes. Most obviously, it might be considered in-
evitable that medical publishing’s financial dependency
on the pharmaceutical industry should lead to timid edi-
torial standards and incomplete measures. But against
such considerations must be set the principled record of
some ICMJE editors in resisting commercial influence,
and the organization’s substantial achievements, for in-
stance on trial registration.
In fact, a welter of factors probably contribute to the
weaknesses in ICMJE policy. These likely include editors’
historical preoccupation with the problem of author ac-
countability, which while important has reduced consid-
eration of other issues; inadequate understanding of
commercial practices; the assiduous public relations ma-
neuverings of the publications-marketing trade; the cul-
tural haughtiness of medicine, whose emphasis on
professional qualification, status and authority leads nat-
urally to the denigration of writers and elevation of key
opinion leaders; the cultural insecurity of academic
medicine, tacitly compliant with corporate science but
clinging to the eidolon of its own lost sovereignty; and a
conjunction of self-interest among the pharmaceuticaland marketing industries, publishing houses, journals,
editors and academic authors, whose finances or careers
all benefit from the prevailing editorial and marketing
culture.
Finally there are conceptual shortcomings within edi-
torial thought, among which the most interesting is per-
haps the issue of attribution. Medicine’s editors must
understand that attribution is multi-faceted and that
even if an article meticulously and fully discloses the role
of all its contributors and stakeholders – and this is
rarely the case in contemporary industry literature – it
will remain poorly attributed if the most prominent fea-
tures of its attribution do not identify to the reader the
dominant parties in its provenance and development.
The publication ethics community too has been pre-
occupied with the important issues of documentation
and disclosure to such a degree that it has largely failed
to address the importance of communication with the
reader. The marketing trade continues to profit from an
understanding of attribution subtler than that of editors
and ethicists alike.
Suggested developments of the Recommendations
Table 3 summarizes for discussion some areas of poten-
tial improvement for the Recommendations in respect of
industry. In addition to these, the ICMJE should work
alongside academic institutions and societies to achieve
an outright ban on advocacy marketing – defined as the
dominant attribution of commercially-owned, instigated
or financed projects to academics and their institutions.
It is reasonable for academics to work with industry in
the clinical evaluation of commercial drugs, and to par-
ticipate in reporting the findings to their medical col-
leagues; but such projects should always be presented as
commercial ones with academic involvement, not the
other way round.
Furthermore, the ICMJE should apply the principles of
disclosure it requires of authors to itself. No interest dis-
closures are currently to be found on the ICMJE website
or in the Recommendations, nor is there information on
how the ICMJE Recommendations, secretariat, meetings
and other activities are organized and financed. This is
unacceptable – especially since some ICMJE member
journals, who pay the salaries of editors who decide the
ICMJE rules, belong to commercial publishing houses,
profit from reprint or advertising sales to industry, or
are stocked with industry manuscripts.
Conclusions
The ICMJE Recommendations are limited in their cap-
acity to prevent commercial bias, but provide valuable
protection against the worst potential commercial
abuses of literature, such as low methodological stan-
dards, guest authorship and nondisclosure of industry
Table 3 Future development of the ICMJE Recommendations: suggested policies with respect to industry




• Develop specific section on commercial publications.
• Encourage CONSORT to develop a specific commercial schedule.
• Do not refer users to self-interested trade guidelines [22–24].
• Initiative to ban advocacy-based marketing in scholarly publications.
Data sharing • Full rights of access to study protocols, clinical study reports, deidentified patient data including clinical record forms.
• Unrestricted freedom of data analysis, comparison and pooling.
• Database access/analysis rights limited to bona fide academic research groups.
Attribution • Guidance on balanced attribution, ensuring conspicuity of lead contributors – including companies as corporate entities.
• Guidance on author sequence, corporate authorship.
• Cease ICMJE support for ghostwriting – all major contributors to studies/manuscripts, including writers, required to be coauthors.
• Up-front reader notification of commercial projects (e.g. company named in title or as a lead author).
• Role-based contributor listings, including company roles (instigation, finance, product marketing, data ownership).
• Cross-media standard on attribution/labeling.
• New NLM publication type – “Commercial”.
• Work with NLM, CRediT initiative to develop new PubMed-listed categories of credit alongside author – including
categories suitable for companies.
Interest
disclosures
• Financing company’s interests and author relationships identified in Abstract.
• Online grid of all stakeholder interests including authors, contributors, companies and journal.
• Initiative to establish public repositories for comprehensive author interest disclosures.
Matheson BMC Medical Ethics  (2016) 17:20 Page 9 of 10involvement. The Recommendations have also been used
to raise research standards, for instance in trial registra-
tion and the emerging guidance on data sharing. Unfor-
tunately, much of the ICMJE guidance with respect to
industry remains weak and incomplete, and advocacy-
based marketing is directly facilitated. The ICMJE must
bear a degree of responsibility for deficiencies in the
quality of medical literature, to the extent that these fail-
ings are overlooked or even succored by the standards
the ICMJE applies. One must however conclude by sup-
porting the ICMJE Recommendations as a work continu-
ally in progress, by acknowledging their many beneficial
effects on research and publication standards including
in commercial literature, by encouraging their continu-
ing evolution, and by asserting the value of these flawed
but essential guidelines.




Availability of data and materials
The ICMJE Recommendations, website and editorials are
available online at www.icmje.org.
Abbreviations
ICMJE: International Committee of Medical Journal Editors;
CONSORT: Consolidated Standards of Reporting Trials.
Competing interests
Between 1993 and 2012 the majority of my income came from consultancy
and writing services provided to pharmaceutical corporations, either directly
or via marketing agencies. In 2015 I acted as a paid expert witness on behalf
of the plaintiffs in a US federal legal action against a pharmaceutical
corporation.I received no support, remuneration or benefits of any kind for researching
and writing this article.
I consider myself a supporter of bona fide scientific research including
for-profit industry research, but an opponent of marketing practices in the
conception, design, conduct and communication of scientific research.
Between 1993 and 2012, I worked each year either full or part-time within
the pharmaceutical marketing sector, specializing in strategic analysis,
publications planning, meetings and ghostwriting. In 2015 I acted as a paid
expert witness on behalf of plaintiffs in a US government action involving a
pharmaceutical corporation.
Authors’ contributions
The author (Alastair Matheson) was solely responsible for all aspects of
conception and design, and solely wrote, approves and takes responsibility
for the manuscript.
Authors’ information
AM is an independent consultant and researcher based in Toronto, Canada,
with research interests in publication ethics, guidelines, trade practices and
the cultural interface between commerce and academia. He worked for 15
over years in the pharmaceutical marketing and trade publications sector,
with working experience of market and competitor analysis, product
positioning, publication planning, academic liaison and manuscript
development.
Funding
I received no funding from any source in researching and writing this article.
I am not affiliated to any institution.
Received: 4 December 2015 Accepted: 24 March 2016
References
1. Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold
"HRT". PLoS Med. 2010;7:e1000335.
2. Matheson A. Corporate science and the husbandry of scientific and medical
knowledge by the pharmaceutical industry. BioSocieties. 2008;3:355–82.
3. Sismondo S. Ghost management: how much of the medical literature is
shaped behind the scenes by the pharmaceutical industry? PLoS Med.
2007;4:e286.
4. Fugh-Berman A, McDonald CP, Bell AM, Bethards EC, Scialli AR. Promotional
tone in reviews of menopausal hormone therapy after the Women's Health
Initiative: an analysis of published articles. PLoS Med. 2011;8:e1000425.
5. Smith R. Medical journals are an extension of the marketing arm of
pharmaceutical companies. PLoS Med. 2005;2:e138.
Matheson BMC Medical Ethics  (2016) 17:20 Page 10 of 106. Lexchin J. Those who have the gold make the evidence: how the
pharmaceutical industry biases the outcomes of clinical trials of
medications. Sci Eng Ethics. 2012;18:247–61.
7. Gotzsche P. Deadly Medicines and Organised Crime: How Big Pharma has
Corrupted Healthcare. London: Radcliffe, 2013.
8. Healy D. Pharmageddon. Berkeley: University of California Press; 2013.
9. Lundh A, Krogsbøll LT, Gøtzsche PC. Sponsors' participation in conduct and
reporting of industry trials: a descriptive study. Trials. 2012;13:146. doi:10.
1186/1745-6215-13-146.
10. Tuech JJ, Moutel G, Pessaux P, Thoma V, Schraub S, Herve C. Disclosure of
competing financial interests and role of sponsors in phase III cancer trials.
Eur J Cancer. 2005;41:2237–40.
11. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in
clinical trials: a systematic review. PLoS One. 2012;7(7):e41174.
12. Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, et al.
Restoring Study 329: efficacy and harms of paroxetine and imipramine in
treatment of major depression in adolescence. BMJ. 2015;351:h4320.
13. Amsterdam JD, McHenry LB. The paroxetine 352 bipolar trial: A study in
medical ghostwriting. Int J Risk Saf Med. 2012;24:221–31.
14. Matheson A. How industry uses the ICMJE guidelines to manipulate
authorship—and how they should be revised. PLoS Med. 2011;8:e1001072.
15. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and
ghostwriting in publications related to rofecoxib: a case study of industry
documents from rofecoxib litigation. JAMA. 2008;299:1800–12.
16. Moynihan R. Key opinion leaders: independent experts or drug
representatives in disguise? BMJ. 2008;336:1402–3.
17. White Paper: Key Opinion Leader Identification and Selection. A Pharma Matters
Report. Thomson Reuters, January 2009. Available: http://www.slideshare.net/
driceman/kol-management?related=1 Accessed 12 Feb 2015.
18. Sismondo S. Key opinion leaders and the corruption of medical knowledge: what
the Sunshine Act will and won't cast light on. J Law Med Ethics. 2013;41:635–43.
19. International Committee of Medical Journal Editors (ICMJE)
Recommendations for the Conduct, Reporting, Editing, and Publication of
Scholarly Work in Medical Journals (ICMJE Recommendations). Available:
http://www.icmje.org/recommendations/. Accessed 12 Feb 2015.
20. Horton R. The dawn of McScience. New York Review of Books. 11 Mar 2004.
21. Angell M. The truth about drug companies: how they deceive us and what
to do about it. New York: Random House; 2004.
22. Scott-Lichter D and the Editorial Policy Committee, Council of Science
Editors. (2012) CSE’s White Paper on Promoting Integrity in Scientific Journal
Publications, 2012 Update. Available: http://www.councilscienceeditors.org/
i4a/pages/index.cfm?pageid=3331. Accessed 12 Feb 2015.
23. Jacobs A, Wager E. European Medical Writers Association (EMWA) guidelines
on the role of medical writers in developing peer-reviewed publications.
Curr Med Res Opin. 2005;21:317–22.
24. Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good
publication practice for communicating company-sponsored medical
research: GPP3. Ann Intern Med. 2015;163:461–4.
25. Pharmaceutical Research Manufacturers of America. (2011) Principles on
Conduct of Clinical Trials and Communication of Clinical Trial Results.
Washington, DC. Available: http://www.phrma.org/sites/default/files/105/
042009_clinical_trial_principles_final.pdf. Accessed 12 Feb 2015.
26. Leo J, Lacasse JR, Cimino AN. Why does academic medicine allow
ghostwriting? A Prescription for Reform. Soc. 2011;48:371–5.
27. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al.
Clinical trial registration: a statement from the International Committee of
Medical Journal Editors. JAMA. 2004;292(11):1363–4.
28. Clinicaltrials.gov. FDAAA 801 Reporting Requirements. https://www.
clinicaltrials.gov/ct2/manage-recs/fdaaa. Accessed 12 Feb 2015.
29. Consolidated Standards of Reporting Trials (CONSORT). http://www.consort-
statement.org/. Accessed 12 Feb 2015.
30. Steinbrook R, Kassirer JP. Data availability for industry sponsored trials: what
should medical journals require? BMJ. 2010;341:c5391.
31. Lundh A, Krogsbøll LT, Gøtzsche PC. Access to data in industry-sponsored
trials. Lancet. 2011;378(9808):1995–6.
32. Gøtzsche PC. Why we need easy access to all data from all clinical trials and
how to accomplish it. Trials. 2011;12:249. doi:10.1186/1745-6215-12-249.
33. AllTrials campaign. http://www.alltrials.net/. Accessed 12 Feb 2015.
34. Taichman DB, Backus J, Baethge C, Bauchner H, de Leeuw PW, Drazen JM,
et al. Sharing clinical trial data: a proposal from the International Committee
of Medical Journal Editors. Lancet. 2016;387(10016):e9–11.35. Rose SL, Krzyzanowska MK, Joffe S. Relationships between authorship
contributions and authors' industry financial ties among oncology clinical
trials. J Clin Oncol. 2010;28:1316–21.
36. DeBakey L, DeBakey S. Ghostwriters: not always what they appear. JAMA.
1995;274:870–1.
37. Rennie D. Integrity in scientific publishing. Health Serv Res. 2010;45:885–96.
38. Huth EJ, Case K. The URM: twenty-five years old. Science Editor. 2004;27:17–21.
39. Rennie D, Flanagin A. Authorship! Authorship! Guests, ghosts, grafters, and
the two-sided coin. JAMA. 1994;271:469–71.
40. Hirsch LJ. Conflicts of interest, authorship, and disclosures in industry-related
scientific publications: the tort bar and editorial oversight of medical
journals. Mayo Clin Proc. 2009;84:811–21.
41. Camby I, Delpire V, Rouxhet L, Morel T, Vanderlinden C, Van Driessche N,
et al. Publication practices and standards: recommendations from GSK
Vaccines' author survey. Trials. 2014;15:446.
42. Jacobs A, Carpenter J, Donnelly J, Klapproth JF, Gertel A, Hall G, et al. The
involvement of professional medical writers in medical publications: results
of a Delphi study. Curr Med Res Opin. 2005;21:311–6.
43. Neurology. Information for authors. http://www.neurology.org/site/misc/
auth2.xhtml. Accessed 11 Feb 2016.
44. Brand A, Allen L, Altman M, Hlava M, Scott J. Beyond authorship: attribution,
contribution, collaboration and credit. Learned Publishing. 2015;28:151–5.
45. Consortia Advancing Standards in Research Administration Information
(CASRAI). http://casrai.org/About. Accessed 30 Mar 2016.
46. Rennie D, Yank V, Emanuel L. When authorship fails. A proposal to make
contributors accountable. JAMA. 1997;278:579–85.
47. Smith R. Authorship: time for a paradigm shift? BMJ. 1997;314:992.
48. Smith R. Let's simply scrap authorship and move to contributorship. BMJ.
2012;344:e157.
49. Fotion N, Conrad CC. Authorship and other credits. Ann Int Med. 1984;100:592–4.
50. Resnick DB. A proposal for a new system of credit allocation in science. Sci
Eng Ethics. 1997;3:237–43.
51. Drazen JM. Revisiting the commercial-academic interface. N Engl J Med.
2014;372(19):1853–4.
52. Loder E, Brizzell C, Godlee F. Revisiting the commercial-academic interface
in medical journals. BMJ. 2015;350:h2957.
53. Lundh A, Barbateskovic M, Hróbjartsson A, Gøtzsche PC. Conflicts of interest at
medical journals: the influence of industry-supported randomised trials on
journal impact factors and revenue - cohort study. PLoS Med. 2010;7:e1000354.
54. Handel AE, Patel SV, Pakpoor J, Ebers GC, Goldacre B, Ramagopalan SV. High
reprint orders in medical journals and pharmaceutical industry funding:
case-control study. BMJ. 2012;344:e4212.
55. Lundh A, Hróbjartsson A, Gøtzsche PC. Income from reprints creates a
conflict of interests. BMJ. 2012;345:e4970. doi:10.1136/bmj.e4970.
56. Rasmussen K, Schroll J, Gøtzsche PC, Lundh A. Under-reporting of conflicts of
interest among trialists: a cross-sectional study. J R Soc Med. 2015;108:101–7.
57. ORCID. Connecting research and researchers. http://orcid.org/.
Accessed 12 Feb 2015.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
